Septa Pharmaceuticals Acquires CeeNU from Bristol Myers Squibb

Septa Pharmaceuticals Inc. has finalized the acquisition of the alkylating agent CeeNU (Lomustine) from Bristol Myers Squibb, Canada. Effective June 29, 2026, the deal bolsters the Mississauga-based company’s oncology portfolio and signals a move to secure long-term supply for patients battling brain tumors and Hodgkin’s lymphoma.

Corp and Tech·July 15, 2026·reads: 352

The transition integrates a specialized chemotherapy treatment into Septa’s existing oncology lineup, a move the company describes as a priority for maintaining uninterrupted patient access. As global healthcare supply chains face increasing complexity, the firm is coordinating with regulatory bodies and partners to stabilize the distribution of the medication throughout Canada.

Devinder K., President and CEO of Septa Pharmaceuticals, noted that the company is focusing on seamless integration with medical professionals who rely on the drug for critical care. Beyond this acquisition, Septa is actively pursuing further licensing opportunities and international partnerships to expand its reach and commercialize high-impact therapies, aiming to bridge existing gaps in the global pharmaceutical market.